Suppr超能文献

5,5-二苯基乙内酰脲与大鼠肝微粒体蛋白不可逆结合的研究。

Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins.

作者信息

Pantarotto C, Arboix M, Sezzano P, Abbruzzi R

出版信息

Biochem Pharmacol. 1982 Apr 15;31(8):1501-7. doi: 10.1016/0006-2952(82)90372-0.

Abstract

5,5-Diphenylhydantoin irreversibly binds to rat liver microsomes and the process requires NADPH and O2. Proteins binding was significantly enhanced when experiments were carried out with liver microsomal preparations from beta-naphthoflavone and 3-methylcholanthrene pretreated animals whereas pretreatment with phenobarbital significantly reduced it. Carbon monoxide, beta-diethylaminoethyl-diphenylpropylacetate and glutathione inhibited drug covalent binding to microsomal proteins. In contrast, enhanced drug binding was observed when trichloropropene oxide and cyclohexene oxide, two epoxide hydrolase inhibitors, were added to the incubation mixture. 5,5-Diphenylhydantoin in vitro metabolism was quantitatively determined by gas liquid chromatography with selected ion monitoring. A good correlation seems to exist between drug covalent binding and the microsomal process of 5,5-diphenylhydantoin hydroxylation to 5-(4-hydroxyphenyl)-5-phenylhydantoin. The results presented support a previous hypothesis on the intermediacy of arene oxides in the biotransformation of this drug.

摘要

5,5-二苯基乙内酰脲与大鼠肝微粒体不可逆结合,该过程需要还原型辅酶Ⅱ(NADPH)和氧气。用β-萘黄酮和3-甲基胆蒽预处理动物的肝微粒体制剂进行实验时,蛋白质结合显著增强,而用苯巴比妥预处理则显著降低。一氧化碳、β-二乙氨基乙基二苯基丙基乙酸酯和谷胱甘肽抑制药物与微粒体蛋白质的共价结合。相反,当向孵育混合物中加入两种环氧水解酶抑制剂环氧氯丙烷和氧化环己烯时,观察到药物结合增强。采用选择离子监测气相色谱法定量测定5,5-二苯基乙内酰脲的体外代谢。药物共价结合与5,5-二苯基乙内酰脲羟基化为5-(4-羟苯基)-5-苯基乙内酰脲的微粒体过程之间似乎存在良好的相关性。所呈现的结果支持了先前关于该药物生物转化中芳烃氧化物中间体的假说。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验